Skip to main content
HLB Therapeutics Co.,Ltd. logo

HLB Therapeutics Co.,Ltd. — Investor Relations & Filings

Ticker · 115450 ISIN · KR7115450009 KO Manufacturing
Open in API
Filings indexed 444 across all filing types
Latest filing 2023-05-30 Share Issue/Capital Cha…
Country KR South Korea
Listing KO 115450

About HLB Therapeutics Co.,Ltd.

https://hlbtherapeutics.co.kr/en/

HLB Therapeutics Co., Ltd. is a biopharmaceutical company specializing in the development of innovative, first-in-class drugs for rare and intractable diseases. The company's clinical-stage pipeline focuses on addressing unmet medical needs in ophthalmology and oncology. Key development programs include RGN-259, a therapeutic agent for Dry Eye Disease and Neurotrophic Keratopathy, and OKN-007 for the treatment of Glioblastoma Multiforme. Additionally, the company is advancing a Natural Killer (NK) cell therapy through late-stage clinical trials to provide new therapeutic options for patients.

Recent filings

Filing Released Lang Actions
[기재정정]전환청구권행사(제14회차)
Share Issue/Capital Change Classification · 100% confidence The document is a regulatory filing from HLB Therapeutics regarding the exercise of conversion rights for convertible bonds (14th series). It details the conversion of debt into equity, which directly impacts the company's capital structure and share count. This type of filing is categorized as a 'Share Issue/Capital Change' (SHA) because it reports the issuance of new shares resulting from the conversion of convertible securities.
2023-05-30 Korean
전환청구권행사(제14회차)
Share Issue/Capital Change Classification · 100% confidence The document is a regulatory filing from HLB Therapeutics regarding the exercise of conversion rights (전환청구권행사) for convertible bonds (제14회차). This involves the issuance of new shares resulting from the conversion of debt into equity, which directly impacts the company's capital structure and share count. According to the provided definitions, announcements regarding new share issues or capital changes fall under the 'SHA' category.
2023-05-22 Korean
전환가액의조정(제13, 14회차)
Capital/Financing Update Classification · 100% confidence The document is a formal regulatory filing from HLB Therapeutics regarding the adjustment of conversion prices for convertible bonds (13th and 14th series). It details the specific price changes, the calculation methodology based on market price fluctuations, and the impact on the number of convertible shares. This type of disclosure is a standard capital structure update related to financing instruments, which falls under the 'Capital/Financing Update' category.
2023-05-16 Korean
분기보고서 (2023.03)
Interim / Quarterly Report Classification · 100% confidence The document is a '분기보고서' (Quarterly Report) for HLB Therapeutics Co., Ltd. covering the period from January 1, 2023, to March 31, 2023. It contains detailed financial information, business operations, and management discussions, which aligns with the definition of an Interim/Quarterly Report (IR). Q1 2023
2023-05-15 Korean
기업설명회(IR)개최
Report Publication Announcement Classification · 100% confidence The document is a formal announcement regarding the scheduling and details of an Investor Relations (IR) event (기업설명회). It provides the date, location, target audience, and purpose of the meeting. Since it is an announcement of an upcoming presentation rather than the presentation slides themselves, and it is a regulatory disclosure of an event, it fits the definition of a Report Publication Announcement or a general regulatory filing regarding corporate events. Given the specific nature of announcing an IR event, it is classified as a Report Publication Announcement (RPA).
2023-05-10 Korean
주식등의대량보유상황보고서(일반)
Major Shareholding Notification Classification · 100% confidence The document is a '주식등의 대량보유상황보고서' (Report on Large Shareholding), which is a standard regulatory filing in South Korea under the Capital Markets Act. It details changes in share ownership, including the exclusion of a special related party (Nomad No. 1 Fund) and the forfeiture of call options. This type of filing is specifically categorized as a 'Major Shareholding Notification' (MRQ) in the provided schema.
2023-05-02 Korean

Browse filings by year

9 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.